Fundraising FoxTensixty
Cambridge, US · Founded 2021 · Delaware corporation · 4 known investors
Find your way into Tensixty
Sign up to see every warm intro you have to Tensixty
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Tensixty team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
TenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.
Founders & leadership
Tensixty was founded in 2021 by Daniel Montoro and Karthik Jagadeesh.
DM
Daniel MontoroCo-founderDaniel Montoro is CEO and co-founder of TenSixty Bio, which develops antibody therapeutics for cancer using machine learning and cell biology. He completed research in stem cell and developmental biology at Stanford, Harvard, and the Broad Institute.
KJ
Karthik JagadeeshCo-founder
CM
Christoph MuusNamed on SEC filing
Board
DN
Dipchand NisharBoard director
SC
Investors · 4
Civilization Ventures Management, Llclisted by Civilization Ventures Management, LlcTiburon · $1M – $10M
How we know: Civilization Ventures Management, Llc's portfolio page · the VCSheet dataset · Not right? Tell us
.png)
General Catalystlisted by General CatalystSan Francisco · $30M
How we know: General Catalyst's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$7.2M disclosed across 1 round · 2022
▶$7.2MraisedAug 2022 · 11 investors · BiotechnologyRule 506(b)
▶$7.2MraisedAug 2022 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christoph MuusDirector
- Dipchand NisharDirector
- Daniel MontoroExecutive Officer, Director
- Karthik JagadeeshExecutive Officer, Director
- Sara ChoiDirector
- Offering amount
- $7.2M
- Amount sold
- $7.2M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
Tenax TherapeuticsTenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
Ten63 TherapeuticsTen63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
TenvieTenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases. The company is led by a team with expertise in biotech and precision medicine, targeting treatments for patients and caregivers affected by neurological conditions.
General CatalystGeneral Catalyst is a global venture capital and investment firm that backs and builds technology companies across sectors including AI, healthcare, and defense, and manages assets on behalf of its portfolio. The firm also acquires and transforms businesses, such as a hospital system, and incubates its own "hatched" companies.
Tenaya TherapeuticsTenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease. This page is a board/leadership team bio page.
Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.
Octant BioOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Dialectic TherapeuticsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies working in the same space as Tensixty.
Frequently asked questions
- What does Tensixty do?
- TenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.
- Who founded Tensixty?
- Tensixty was founded by Daniel Montoro, Karthik Jagadeesh in 2021.
- Who are Tensixty's investors?
- Tensixty's investors include Civilization Ventures Management, Llc, General Catalyst, Wing, The Engine Ventures.
- How much funding has Tensixty raised?
- Tensixty has disclosed $7.2M raised across 1 round.
- Where is Tensixty headquartered?
- Tensixty is headquartered in Cambridge, US.